Abatacept is a soluble recombinant fusion protein, which consists of extracellular domain of human CTLA-4 and human Fc segment. Abatacept specifically blocks CD28-mediated costimulatory signals by binding to CD80 and CD86 on the surface of antigen presenting cells with high affinity, thus inhibiting T cell activation. Abatacept is often used to study rheumatoid arthritis, autoimmune reaction and immune disorder caused by LRBA deficiency.

Animal Model: Male Lewis rats (6-9 weeks old) with weights of 150-175 g. Dosage: 10 mg/kg (i.v.), 20 mg/kg (s.c. single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29. Administration: i.v. or s.c. [2]

阿巴西普, CTLA4lg, BMS-188667

Monoclonal

Unconjugated